KBC Group’s ImmunityBio IBRX Stock Holding History

KBC Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$90K	Hold	10,307	–	–	﹤0.01%	1481
2026 Q1	$79K	Buy	+10,307	New	+$70.6K	﹤0.01%	1459

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KBC Group's IBRX Position: Q2 2026 in Review

KBC Group held its ImmunityBio (IBRX) position steady in Q2 2026 at 10,307 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #1481.

KBC Group first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

KBC Group held 10,307 shares of ImmunityBio worth $90K as of Q2 2026.
KBC Group left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1481 holding.
KBC Group first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.